Mobidiag, AB ANALITICA Sign Distribution Agreement
News Apr 07, 2017
Mobidiag Ltd has announced an agreement with AB ANALITICA, specialized in the development and the sale of diagnostic systems for professional use, for the distribution of the Amplidiag® product line. Under this three-year agreement, AB ANALITICA becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Italy.
“For the past months, we have been significantly extending our in vitro diagnostics suite of products. In order to make our IVD tests and instruments accessible throughout Europe, we are continuing the expansion of our distributor network to be able to support our customers more locally. With strong background in clinical microbiology and molecular diagnostics and a wide sales network, AB ANALITICA is the right partner to distribute our products in Italy”, said Tuomas Tenkanen, CEO at Mobidiag.
“AB ANALITICA has over 25 years of experience in the diagnostic market and is renowned for providing high-quality molecular diagnostic solutions. The agreement with Mobidiag enables us to complete our product offering to customers with an extensive range of IVD tests and instruments for infections found in stool samples” from Mikkel Johansen, Managing director at AB ANALITICA.
The distribution agreement is effective immediately and covers all Amplidiag® IVD tests (Amplidiag® H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag® C. difficile+027, Amplidiag® Bacterial GE and the two upcoming tests: Amplidiag® Viral GE and Amplidiag® CarbaR+MCR) as well as the Amplidiag® Easy system.
Tweak to Technique Could Bolster Disease DetectionNews
A team of Stanford researchers has developed a technique that they hope could more precisely detect diseases or disorders such as cancer or a heart attack.READ MORE
Immune Cells That Keep Gut Fungi Under Control IdentifiedNews
Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists.READ MORE
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE